旌准医疗 (Beijing Jingzhun Medical Technology Co., Ltd.) is a Beijing-based company founded in 2015 that provides end-to-end molecular diagnostic solutions focused on blood diseases. The company has built six technology platforms and offers products and services including real-time qPCR, Sanger sequencing, high-throughput NGS, capillary electrophoresis fragment analysis, flow cytometry, and visual molecular pathology-related tests and reagents. It serves blood oncology, transplantation, molecular pathology and cell immunotherapy fields, supporting in-hospital testing, diagnosis, efficacy evaluation and prognosis monitoring. The company announced completion of about ¥200 million in a C round and plans to use proceeds to advance large-scale clinical trials and registration filings for its molecular diagnostic reagent products, strengthen market promotion, replicate its overall-solution model in core tertiary hospitals, boost sales revenue, and continue innovative product R&D. Management targets regulatory expansion (six Class III blood-disease registrations in 2021 and more than 30 by end-2024) to build competitive barriers and become an industry leader. The firm is targeting rapid geographic expansion from its regional base into broader national markets to capture a large addressable patient population.

Total raised

$31M

Funding rounds

1

Latest round

Series C

Latest activity

Apr 2021